The Journal of Immunology, Vol 141, Issue 2 398-403, Copyright © 1988 by American Association of Immunologists

ARTICLES

A regulatory role for the CD4 and CD8 molecules in T cell activation

H Schrezenmeier and B Fleischer
Department of Medical Microbiology and Immunology, University of Ulm, Federal Republic of Germany.

The role of the CD4 and CD8 molecules in T cell activation is presently a matter of controversy. Although their role as associative binding elements to MHC class II or class I is well documented, their influence on the triggering process in unclear. Because antibodies to CD4 or CD8 block T cell activation in the absence of their respective ligands, a negative signaling by these molecules has been suggested. However, recent experimental evidence argues against a negative regulatory effect of these molecules, since, e.g., simultaneous cross-linking of TCR and CD4 leads to enhanced T cell activation. Therefore, a current model suggests that the association of TCR and CD4 in the membrane gives a positive signal essential for triggering. In this report we present evidence that this model is likely to be too simple. Anti-CD4 and CD8 antibodies inhibit alternative, nonreceptor pathways of T cell triggering via Tp103 and Tp44 in the absence of class II positive accessory or target cells. These antibodies also inhibit bypass activation of T cells by phorbol ester and calcium ionophore in an accessory cell-free system. Furthermore, if the CD4 or CD8 molecules are removed from the cell surface by antibody-induced modulation, the proliferative and cytotoxic response of T cell clones is enhanced. This enhancement is also observed if resting peripheral blood T cells are used as responder cells. These data show that the CD4 or CD8 molecules have a complex regulatory function in T cell activation beyond the requirement for co-cross-linking with the TCR.

This article has been cited by other articles:

				T. W. Hepburn, M. C. Totoritis, and C. B. Davis Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis Rheumatology, January 1, 2003; 42(1): 54 - 61. [Abstract] [Full Text] [PDF]

				A. Sharma, C. B. Davis, L. A. P. Tobia, D. C. Kwok, M. G. Tucci, E. R. Gore, D. J. Herzyk, and T. K. Hart Comparative Pharmacodynamics of Keliximab and Clenoliximab in Transgenic Mice Bearing Human CD4 J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 33 - 41. [Abstract] [Full Text]

				R. G. Carroll, J. L. Riley, B. L. Levine, Y. Feng, S. Kaushal, D. W. Ritchey, W. Bernstein, O. S. Weislow, C. R. Brown, E. A. Berger, et al. Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+ T Cells Science, April 11, 1997; 276(5310): 273 - 276. [Abstract] [Full Text]